Alnylam Q1 net product revs $1.04B (+121%); GAAP EPS $1.51 vs -$0.14; reaffirms FY26 guidance

ALNYLAM PHARMACEUTICALS, INC.

Global net product revenues $1,036M, up 121% YoY; total TTR revenues $910M (+153%).
GAAP net income $206M vs loss $18M; GAAP diluted EPS $1.51; non-GAAP EPS $1.99.
Reiterates FY26 combined net product revenue guidance of $4.9B-$5.3B.
AMVUTTRA (vutrisiran) net product revenues $890M; TRITON-CM expanded to ~1,750 patients.
Initiated Phase 1 obesity trial (ALN-2232) and new collaborations with Viz.ai, AHA, Tenaya, Helix.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.